Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 5/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.45 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | ASPH | Q12797 | 1/20 | 0.39 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | P4HB | P07237 | 2/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1417702 | 0.79 | TRPV4 (0.53) | XDHSLC22A12TAS2R14MRGPRX4TRPV4 | |
| SCHEMBL31171336 | 0.79 | MAP2K1 (0.41) | XDHSLC22A12TAS2R14MAP2K1 | |
| SCHEMBL3171347 | 0.74 | KIF11 (0.49) | TRPV4KIF11P4HB | |
| SCHEMBL2387492 | 0.74 | ASPH (0.46) | TAS2R14ASPH | |
| SCHEMBL25111974 | 0.74 | EPRS1 (0.46) | TAS2R14ASPH | |
| SCHEMBL8389880 | 0.74 | ASPH (0.42) | TAS2R14ASPHMAP2K1 | |
| SCHEMBL29334051 | 0.74 | ASPH (0.42) | TAS2R14ASPH | |
| SCHEMBL30483541 | 0.74 | EPRS1 (0.46) | TAS2R14ASPH | |
| SCHEMBL24566862 | 0.74 | KDM4E (0.43) | ASPH | |
| SCHEMBL7566278 | 0.70 | P4HB (0.46) | XDHSLC22A12TAS2R14MRGPRX4TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158368-A1 | Pyrrolidine Main Protease Inhibitors as Antiviral Agents | ABBVIE INC. (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2024081351-A1 | PYRROLIDINE MAIN PROTEASE INHIBITORS AS ANTIVIRAL AGENTS | ABBVIE INC. (US) | 2024-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158368-A1 | Pyrrolidine Main Protease Inhibitors as Antiviral Agents | PREP, PEPD, DNPEP | XDH 2923/4885SLC22A12 4488/4885TAS2R14 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.